Latest Breaking News On - Australasian gastro intestinal trials group - Page 1 : comparemela.com

Landmark Study Uses Lab-Grown Tumours to Predict Treatment Outcomes

Landmark Study Uses Lab-Grown Tumours to Predict Treatment Outcomes
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.

Shan liJordan clarkeDmitri mouradovAnuratha sakthianandeswarenMichelle palmieriMargaret leePeter gibbsOliver sieberKazim jalaliAntony burgessYumiko hirokawaEvelyn leongHelen brasierLaboratory headCancer council victoriaIntestinal trials group

Imugene to open new PD1-Vaxx Phase 2 bowel cancer clinical trial in UK and Australia

Imugene Ltd (ASX:IMU, OTC:IUGNF) is preparing 10 clinical trial sites in Australia and the UK for a new PD1-Vaxx Phase 2 colorectal (CRC) cancer clinical.

United kingdomTony dhillonLeslie chongIntestinal trials groupUniversity of southampton clinical trials unitImugene ltdUniversity of southamptonVaxx phaseRoyal surrey hospitalAustralasian gastro intestinal trials groupTim priceSouthampton clinical trials unitInvestigator sponsored

Cautiously optimistic about trial | Otago Daily Times Online News

A Dunedin oncologist is "cautiously optimistic" about a clinical trial under way to combat a lethal cancer. Dr Chris Jackson is leading the first.

New zealandNew zealandersChris jacksonLiam willisUniversity of otagoGut cancer foundationIntestinal trials groupPancreatic cancer awareness monthAustralasian gastro intestinal trials groupCancer foundation

FDA Awards Orphan Drug Designation to LSTA1 for Malignant Glioma

FDA Awards Orphan Drug Designation to LSTA1 for Malignant Glioma
onclive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from onclive.com Daily Mail and Mail on Sunday newspapers.

United statesClinical trial centreUniversity of kansas medical centerUniversity of tartuIntestinal trials groupUniversity of sydneyLisata therapeutics incLisata therapeuticsAustralasian gastro intestinal trials groupTrial centreKansas medical

Lisata Therapeutics Announces Enhancements to Ongoing Phase 2b ASCEND Trial of LSTA1

Target enrollment increased to 155 subjects with the addition of a cohort testing a second dose of LSTA1 Results to be used to explore possible conditional approvals globally Futility analysis. | May 24, 2023

New zealandThe university of sydneyNew south walesJohn mendittoExchange commissionCorporate communicationsClinical trial centreLisata therapeutics incIntestinal trials groupNational healthResearch councilClinical trials centreUniversity of sydneyAustralasian gastro intestinal trials groupMedical research councilExecutive vice president